Heparin and atherosclerosis.
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology; D001693:Biological Transport, Active; D001777:Blood Coagulation; D002455:Cell Division; D003172:Complement C1 / Q000378:metabolism; D003174:Complement C1 Inactivator Proteins / Q000378:metabolism; D004727:Endothelium / Q000187:drug effects; D005342:Fibrinolysis; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008071:Lipoprotein Lipase / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood; D008264:Macrophages / Q000378:metabolism; D009130:Muscle, Smooth / Q000166:cytology; D010974:Platelet Aggregation; D013917:Thrombin / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D003172:Complement C1; D003174:Complement C1 Inactivator Proteins; D008075:Lipoproteins, HDL; D014280:Triglycerides; D006493:Heparin; D008071:Lipoprotein Lipase; D013917:Thrombin